ETF Holdings Breakdown of CNTA

News associated with CNTA

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Consensus PT from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-05-05 05:34:53

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Average Price Target from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on […] - 2025-04-10 06:07:13

Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 187.23% […] - 2025-04-02 06:12:49

Guggenheim Reaffirms Buy Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 92.97% from the stock’s previous close. Several other brokerages have […] - 2025-03-28 07:02:42

Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares of the company’s […] - 2025-03-24 08:04:57

Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock […] - 2025-02-19 06:12:50

CNTA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	44,289	USD 548,741 2.3%
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	44,289	USD 548,741 2.3%
Total =		88,578	USD 1,097,482

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer